INTRODUCTION
Group 1 was constituted of 20 horses aged 6 months to 16 years and Group 2 was constituted of 8 donkeys aged 7 months to 19 years.
In vivo, we used the Faecal Egg Count Reduction Test (FECRT) in order to evaluate the fenbendazole effectiveness.
In vitro, in order to evaluate the effectiveness of albendazole, fenbendazole, mebendazole and thiabendazole, two tests were used: Egg Hatch Assay (EHA) and Larval Development Assay (LDA).
Six months prior to this study, in the horse group, ivermectin-based products treatments were carried out. No recorded data regarding the anthelmintic treatments of the donkey group is available. For accuracy, faecal samples were collected directly from the rectal ampulla or immediately after defecation. For each of the collected samples, McMaster and Stoll methods and coprocultures were performed.
FECRT aimed to assess the strongyles intensity and extensivity before (BT) and post-treatment (PT), evaluation of fenbendazole effectiveness in vivo, statistical analysis of the obtained data and identification of the resistant strongyle species.
For EHA, we used serial dilutions from 500 mcg to 0.98 mcg active ingredient/ml. In order to evaluate the strongyles resistance against benzimidazoles, the following parameters were interrelated: hatching percentage and larval development at the reference concentration, the trendline equation, lethal concentration for 50% (LC50) and minimum inhibitory concentration (MIC). The trend line equation was calculated automatically allowing interpretation of resistance risk level.
RESULTS AND DISCUSSION
The stool tests were based on the morphostructural aspects of stage 3 larvae after 14 days of incubation. In the horse group, a predominance of the small strongyle species, especially those of the species Cyathostomum type A was revelead (53.40%) and Cyathostomum type D (with a percentage of 25). No species of the Strongylidae subfamily were identified, confirming the international data reporting a decreased incidence of these species in horses, along with an increased incidence of small strongyles (Cernea et al., 2010) .
In the donkey group, a predominance of small strongyles was observed (Cyathostomum type A 29.33%, Cyathostomum type D 8%), though along with larger strongyles, mainly Triodontophorus spp. (1.33%). Furthermore, a high percentage of Trichostrongylus axei L3 larvae was observed (37.33%) (Tab. 1). The differences observed between the two equine species, in terms of digestive strongyle populations, can be explained by owners' choice of excluding the donkeys from anthelmintic treatments. Thereby, due to interspecific contamination, the donkey strongyle species constitute a reservoir, unaltered by the anthelmintic treatments. Consequently, regardless of the deworming treatments applied, the horses can be recontaminated with resistant strongyles derived from the untreated donkeys, through cohabitation.
FECRT was performed using a fenbendazolebased product. Before the treatment (BT) individual stool samples were collected. Afterwards, fenbendazole was administered in a dose of 7,5 mg/kg bw. 14 days post-treatment (PT), individual stool samples were collected once again, determining EPG, the intensity and the extensivity level.
In the horse group, the average intensity BT was 1595.5 EPG, with a maximum of 4000 EPG. The extensivity level BT was 55%. 14 days PT, all stool samples were negative, reflecting the high efficacy of fenbendazole (Tab. 2).
For the donkey group, results were different. The total EPG determined prior to treatment was 6550, with an intensity of 935.7 and an extensivity of 87.5%. The results, 14 days posttreatment, showed an average intensity of 150 EPG and a decline of the extensivity to 50% (Tab. 2). Fenbendazole proved to be less effective compared to the horse group, even if the donkey group has never been treated with anthelmintics. One may speculate that the donkeys were infected with resistant equine strongyles from the horses.
FECRT statistical interpretation presented a different situation between the two groups. Group 1 had a 100 percentage of reduction, upper and lower limits of 95% thrust interval being null.
This result highlights the maximum effectiveness of the fenbendazole anthelmintic treatment and the fact that the strongyle population found in horses was not resistant to fenbendazole.
Statistical analysis of the data obtained in the donkey group BT and PT showed a 90.83
Tab. 2. The infestation level (EPG) for both groups before treatment (BT) and post-treatment (PT) Group percentage of reduction, lower than the minimum percentage accepted (95%). The confidence interval 95% was 73%. This data showed that the strongyle population found in the donkey group is resistant to fenbendazole. The Egg Hatch Assay (EHA) for albendazole in horses showed a hatching percentage of 100 at the reference concentration and the LC 50 64.32 mcg/ml. The statistical analisys of the trend line equation and parameters a and b showed the correct hatching percentage of 0.3740, much lower than the accepted limit of 50%. The maximal value of Y paramether was -242.42, drawing a negative tendency for the trend line. All data shows the efficacy of albendazole against the strongyle population found in horses (Tab. 3). Similar results were obtained for fenbendazole as well. The LC 50 was 47.31 mcg/ml and the hatching percentage at the reference concentration was 0.0192. The Y parameter value was way lower than for albendazole, reaching -257.17 and inducing a negative tendency for the trend line equation. This test confirms the results obtained by FECRT proving the fenbendazole efficacy.
EHA showed a totally different situation for mebendazole compared to albendazole and fenbendazole. The hatching percentage at the reference concentration was 105.10, showing the weak inhibitory capacity of this active ingredient against strongyle eggs. Even if LC 50 had a negative value of -0.1453 mcg/ml, corroborating the data obtained at the hatching percentage shows us that, in order to obtain a positive value for the LC 50, the test should be made with active ingredient concentrations higher than 5 mcg/ml. These results have no practical relevance because of the too high dosage. The trend line equation had a high positive tendency, the maximal value for Y parameter being 1009.92. Integrated analysis of obtained values shows a weak efficacy of mebendazole over strongyle population found in horses and the risk of inducing the adaptive phenomena for this substance.
EHA thiabendazole testing showed the best results, but we have to take in consideration the fact that, because of its capacity to delay egg hatch, this active ingredient was tested only as standard (Cernea et al., 2010 For mebendazole, in the donkey group, EHA showed an egg hatching percentage of 87.51 at the reference concentration, LC 50 being 1.20 mcg/ ml. These results showed a reduced efficacy. Even so, compared to albendazole and fenbendazole tests, the risk of strongyles developing adaptive phenomena is lower. The Y parameter showed a value of -85.15 and the trend line had a negative tendency. For thiabendazole the results were similar, the egg hatching percentage being 73.93 and the LC 50 -0.085µg/ml, with a highly negative trend line tendency (Y= -1,840.17).
Larval development assay showed similar values in the horse group. MIC value was the same (0.0489 mcg/ml). The sole difference noted regarded the Y parameter. For albendazole, this value was -525.46, for fenbendazole -849.21 and -581.11 for mebendazole and thiabendazole (Tab. 7 and 8). In horses, all LDA results showed a good efficacy of benzimidazoles against strongyle eggs and larvae (Tab. 7 and 8).
For all benzimidazoles, the risk of resistance is negligible, for fenbendazole being the lowest (Y -849.21). Therefore, treatment efficacy would be greater if the therapeutic protocol would consider a sequential administration for 2-3 days or repeating it at 7-14 days. For the donkey group, LDA had similar results as for the horse group. The Y parameter had a value of -1104.10 for albendazole, mebendazole and thiabendazole, and lower for fenbendazole (-1226.83) (Tab. 9 and 10). 
Tab. 4.

